Loading...
XNAS
UG
Market cap27mUSD
Dec 05, Last price  
6.02USD
1D
1.35%
1Q
-29.26%
Jan 2017
-61.16%
Name

United-Guardian Inc

Chart & Performance

D1W1MN
XNAS:UG chart
P/E
8.51
P/S
2.27
EPS
0.71
Div Yield, %
9.97%
Shrs. gr., 5y
Rev. gr., 5y
-2.18%
Revenues
12m
+11.91%
12,134,99612,195,67211,888,56212,292,14713,276,98413,723,07414,338,51213,825,76415,416,89313,449,67914,006,24410,776,86712,968,20513,769,40113,599,08410,986,08113,929,62912,698,50310,885,15412,181,971
Net income
3m
+25.94%
2,617,4832,737,2323,544,3083,162,9313,878,9633,799,6924,716,5304,830,7805,903,3094,050,4164,606,9292,581,1423,844,2904,352,3314,761,7113,304,9784,658,5422,569,5122,581,3703,250,875
CFO
3m
+10.23%
3,172,0302,076,7974,157,0583,412,3854,337,4484,093,3184,437,1295,380,7475,805,0864,480,7525,199,9722,290,4443,992,2874,950,4124,476,1113,594,2405,313,2772,525,1693,144,4803,466,251
Dividend
Jul 23, 20240.35 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.
IPO date
Mar 17, 1980
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT